Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 40.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,862 shares of the biopharmaceutical company's stock after purchasing an additional 8,537 shares during the quarter. Natixis Advisors LLC's holdings in Insmed were worth $2,278,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Darwin Global Management Ltd. boosted its position in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after acquiring an additional 2,463,261 shares during the last quarter. Brown Advisory Inc. purchased a new position in Insmed in the 4th quarter worth approximately $45,773,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Insmed by 59.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock worth $113,748,000 after purchasing an additional 615,000 shares during the last quarter. Capital International Investors grew its position in shares of Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Duquesne Family Office LLC increased its holdings in shares of Insmed by 2,867.4% in the fourth quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock valued at $40,973,000 after purchasing an additional 573,470 shares during the last quarter.

Insider Buying and Selling

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the sale, the insider directly owned 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 129,805 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the completion of the sale, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 599,767 shares of company stock valued at $54,625,108. Company insiders own 3.00% of the company's stock.

Analysts Set New Price Targets

INSM has been the subject of several analyst reports. Wells Fargo & Company upped their target price on Insmed from $119.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, July 22nd. Morgan Stanley raised their price objective on shares of Insmed from $102.00 to $108.00 and gave the stock an "overweight" rating in a research report on Thursday, July 17th. Bank of America boosted their target price on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. UBS Group dropped their price target on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Royal Bank Of Canada lifted their price target on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed has an average rating of "Moderate Buy" and a consensus target price of $109.20.

Insmed Trading Down 1.8%

Shares of INSM stock opened at $109.30 on Friday. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $113.10. The company has a 50 day moving average price of $97.85 and a 200 day moving average price of $82.12. The stock has a market capitalization of $20.74 billion, a P/E ratio of -18.37 and a beta of 0.95. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.94) EPS. Equities research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.